Featured Research

from universities, journals, and other organizations

Zeroing in on heart disease: Innovative strategy pinpoints genes underlying cardiovascular disease risk

Date:
February 28, 2013
Source:
European Molecular Biology Laboratory (EMBL)
Summary:
Studies screening the genome of hundreds of thousands of individuals (known as Genome-wide association studies or GWAS) have linked more than 100 regions in the genome to the risk of developing cardiovascular disease. Researchers are taking these results one step further by pinpointing the exact genes that could have a role in the onset of the disease.

Cells stained for observation by fluorescence microscopy to discover cholesterol-regulatory genes (top left: cholesterol (orange) uptake by cells; top right: free cholesterol (blue) in cells; bottom left: localisation of a protein (green) involved in cholesterol regulation; bottom right: automated image-analysis showing the cell outer membrane (grey) and the cholesterol (white)).
Credit: EMBL/Peter Blattmann and University of Heidelberg/Christian Schuberth

Studies screening the genome of hundreds of thousands of individuals (known as Genome-wide association studies or GWAS) have linked more than 100 regions in the genome to the risk of developing cardiovascular disease. Researchers from the European Molecular Biology Laboratory (EMBL) and the University of Heidelberg, through the joint Molecular Medicine Partnership Unit (MMPU), are taking these results one step further by pinpointing the exact genes that could have a role in the onset of the disease.

Their findings are published today in the online journal PLoS Genetics.

The scientists used a technology called "RNA interference" that can selectively decrease the level of expression of targeted genes. By observing what changes, if any, this decrease causes in cells, researchers can identify the function of the genes and, on a larger scale, objectively test the function of many genes in parallel.

Cholesterol levels in the blood are one of the main risk factors for cardiovascular disease. They are controlled by the amount of cholesterol that cells can take in -- thus removing it from the blood -- and metabolise. The researchers used RNA interference to test the function of each of the genes within 56 regions previously identified by GWAS as being linked with cardiovascular disease. They selectively decreased their action and measured what, if any, changes this induced in cholesterol metabolism. From this they could deduce which of the genes are most likely to be involved in the onset of the disease.

"This is the first wide-scale RNA interference study that follows up on GWAS. It has proven its potential by narrowing down a large list of candidate genes to the few with an important function that we can now focus on in future in-depth studies," explains Rainer Pepperkok at EMBL, who co-led the study with Heiko Runz at the University of Heidelberg.

"In principle, our approach can be applied to any disease that has an observable effect on cells," adds Heiko Runz. "The genes identified here may further our understanding of the mechanisms leading to cardiovascular disease and allow us to improve its prediction and diagnosis."


Story Source:

The above story is based on materials provided by European Molecular Biology Laboratory (EMBL). Note: Materials may be edited for content and length.


Journal Reference:

  1. Blattmann P, Schuberth C, Pepperkok R, Runz H. RNAi–Based Functional Profiling of Loci from Blood Lipid Genome-Wide Association Studies Identifies Genes with Cholesterol-Regulatory Function. PLoS Genetics, 2013; 9 (2): e1003338 DOI: 10.1371/journal.pgen.1003338

Cite This Page:

European Molecular Biology Laboratory (EMBL). "Zeroing in on heart disease: Innovative strategy pinpoints genes underlying cardiovascular disease risk." ScienceDaily. ScienceDaily, 28 February 2013. <www.sciencedaily.com/releases/2013/02/130228171405.htm>.
European Molecular Biology Laboratory (EMBL). (2013, February 28). Zeroing in on heart disease: Innovative strategy pinpoints genes underlying cardiovascular disease risk. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/02/130228171405.htm
European Molecular Biology Laboratory (EMBL). "Zeroing in on heart disease: Innovative strategy pinpoints genes underlying cardiovascular disease risk." ScienceDaily. www.sciencedaily.com/releases/2013/02/130228171405.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins